Biotechnology company Medistem Laboratories, Inc., US, has announced that its recent co-authored article entitled "Endometrial regenerative cells: a novel stem cell population" has received BioMed Central's research article of the year in medicine award. The award recognises excellence in research that has been made universally accessible through open access publication in one of BioMed Central's 170 peer reviewed scientific journals.
The award was presented to Medistem's CEO Thomas Ichim and Dr. Xiaolong Meng at the Royal Society of Medicine in London. The publication is freely available at http://www.translational-medicine.com/content/5/1/57.
Medistem owns intellectual property associated with endometrial regenerative cells and is currently developing a pipeline of therapeutic products around them. Medistem's lead product is based on preventing amputation through restoring blood flow to the limbs of patients with diabetes and advanced peripheral artery disease.
More News in this Theme
